Hormonal
Dapagliflozin (SGLT2 inhibitor) lowers systolic blood pressure through an initial plasma volume contraction followed by a sustained reduction in sympathetic nervous system activity.
If you have type 2 diabetes and high blood pressure, dapagliflozin 10mg daily can help lower your blood pressure. It works by initially reducing blood volume and, over time, by calming the nervous system's stress response on your blood vessels. This happens even after the initial fluid loss stops.
The dapagliflozin-induced plasma volume contraction may contribute to the initial SBP reduction, while a reduction in SNS activity may contribute to the persistent SBP reduction.
Why this rating
Randomized, double-blind, placebo-controlled trial with mechanistic endpoints, though sample size is small (n=66).
Source
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
Charlotte C. van Ruiten et al. · Cardiovascular Diabetology · 2022
DOI 10.1186/s12933-022-01492-x
More from this paper
- Combining Dapagliflozin and Exenatide results in a synergistic blood pressure reduction that exceeds the sum of their individual effects, driven by plasma volume contraction and potentially other mechanisms beyond SNS reduction.Good
- Exenatide (GLP-1 RA) reduces parasympathetic nervous system activity, which may contribute to an increase in heart rate, but does not significantly lower systolic blood pressure on its own in this population.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →